Overview

Like the agency itself, we have dedicated, interdisciplinary practices focusing on each segment of the Food and Drug Administration (FDA) and the Federal Food, Drug and Cosmetic Act (FDCA). We partner with stakeholders in the food, pharmaceutical, health and life sciences, and other affected industries to navigate FDA regulations and agency interactions. Companies, patient organizations and other stakeholders rely on us to provide experienced advice to help them meet regulatory expectations and navigate the FDA when they’re working with new drugs, biologics, and medical devices and related biotechnology or innovative food products and cosmetics.

Drugs and Medical Devices

As a drug and medical device innovator, patient organization or other stakeholder in the drug or device approval process, your success relies on your ability to comply with a complex framework of regulations related to research and development, marketing authorization and post-marketing compliance. We support you throughout the life cycle of a medical product — from the early research stages to the clinic, to Agency submission and approval, and on to post-marketing commitments and ongoing safety monitoring. 

Our experienced team includes attorneys with extensive experience.  Team members have worked on issues before the FDA’s Center for Drug Evaluation and Research including drug and biologics policy matters before the Office of Pharmaceutical Quality and compliance matters (including 483 responses and warning letters) before the Office of Compliance. The team leverages an interdisciplinary bench of attorneys, consultants and scientists to provide you with insight and practical advice. We handle matters including:

  • Clinical trial contracting
  • Research compliance
  • Product development strategy and early agency interactions
  • Patient-focused drug development (including patient advocacy group collaborations)
  • Software as a medical device
  • Current good manufacturing practice (CGMP) and quality system regulations and expectations
  • Laboratory audits
  • Agency determinations (i.e., INDs, IDEs and expanded access)
  • Risk evaluations and mitigation strategies (REMS)
  • Promotional communications and advertising
  • Privacy protection policies and enforcement
  • Post-marketing surveillance

We also support clients as they innovate using advanced manufacturing techniques and platform technologies, artificial intelligence (AI), machine learning (ML), and other software-based technologies.  

Food and Dietary Supplements

Leading food and dietary supplement companies confront critical legal, regulatory and business challenges every day. We help you develop and execute strategies related to the science, economics, markets, government regulation and public relations aspects of the farm to-table cycle. When disputes, regulatory changes, product recalls or legal suits emerge, our regulatory and litigation teams provide peace of mind as you implement new compliance protocols or tackle high-stakes litigation.

Cosmetics

Makers of cosmetics and personal care products must continuously adapt and expand product offerings to reflect the growing desire of consumers to express their beauty and individuality. At the same time, oversight has never been greater, as we watch FDA implement federal legislation to modernize cosmetics regulation. Creative marketing and advertising of these products may fall outside legal parameters and result in enforcement action by regulatory agencies. States have become increasingly involved in cosmetic regulation as it relates to product ingredients and consumer health. We work with you to meet these emerging challenges head-on. We review product ingredients, help navigate registration requirements and advise on prospective advertising and labeling claims that are the basis for legal challenges by regulators and competitors.

Animal Health

Companies making new animal drugs, medicated feeds and feed additives as well as pet food and animal feed need in-depth knowledge to identify applicable regulations and implement efficient development, manufacturing and marketing of animal food and drugs. We guide clients through interactions with the FDA and the United States Department of Agriculture by delivering industry insight and practical advice on complex legal issues related to adverse event reporting, recalls, criminal investigations and product liability.

Insights & Events

Latest

发表文章 March 2025

Breaking the Silence: Challenges and Opportunities in Pediatric Drug Development

1 min read  
最新 March 2025

HHS Rescission of the Richardson Waiver and Unintended Legal Consequences for Drug and Device Manufacturers

After the Department’s Recission of the Richardson Waiver, Drug and Device Industry Loses Powerful Check Against FDA Overreach
6 min read  
最新 March 2025

NIH Funding Guidance; FDA Reinstates Key Staff Amid Industry Pressure; Make America Healthy Again Commission; and the Latest on Tariffs

Biopharma & Medical Devices Briefing
7 min read  
媒体报道 February 2025

Doriann Cain Provides Insight in Navigating HIPAA Compliance With Becker’s Hospital Review

1 min read  
Speaking Engagement Recap February 12, 2025

Hot Topics in Pharmacy Law

1 min read  
最新 February 2025

10-for-1 Deregulation Executive Order: Key Health Policy Issues to Watch

‘Unleashing Prosperity Through Deregulation’
5 min read  
最新 February 2025

Biden’s 11th-Hour Ethylene Oxide Decision Continues the Environmental Protection Agency’s Expansion Into Occupational Safety

But Will It Stick?
5 min read  
Speaking Engagement Recap January 31, 2025

8th Annual Wow! or Yeow!? 2025: FDA 2024 in Review - Webinar

1 min read  
Press Release September 2024

Three Former Federal Prosecutors Join Faegre Drinker’s White Collar Team

5 min read  
Press Release October 2023

Faegre Drinker Adds Leading FDA Regulatory Attorney Joy Sharp in Washington, D.C.

2 min read  
Insights
发表文章 March 2025

Breaking the Silence: Challenges and Opportunities in Pediatric Drug Development

1 min read  
最新 March 2025

HHS Rescission of the Richardson Waiver and Unintended Legal Consequences for Drug and Device Manufacturers

After the Department’s Recission of the Richardson Waiver, Drug and Device Industry Loses Powerful Check Against FDA Overreach
6 min read  
最新 March 2025

NIH Funding Guidance; FDA Reinstates Key Staff Amid Industry Pressure; Make America Healthy Again Commission; and the Latest on Tariffs

Biopharma & Medical Devices Briefing
7 min read  
媒体报道 February 2025

Doriann Cain Provides Insight in Navigating HIPAA Compliance With Becker’s Hospital Review

1 min read  
最新 February 2025

10-for-1 Deregulation Executive Order: Key Health Policy Issues to Watch

‘Unleashing Prosperity Through Deregulation’
5 min read  
最新 February 2025

Biden’s 11th-Hour Ethylene Oxide Decision Continues the Environmental Protection Agency’s Expansion Into Occupational Safety

But Will It Stick?
5 min read  
最新 February 2025

China Issues Final Compliance Guidelines in Regulating the Medical Industry

Compliance Guidelines on Preventing Commercial Bribery Risks for Pharmaceutical Enterprises
7 min read  
最新 January 2025

FDA's Final Rule for Laboratory Developed Tests

Significant Impact on the Future of LDTs and the Labs That Offer Them
4 min read  
最新 January 2025

Assessing the Impact of a Revoked Executive Order on a Medicaid Drug Demonstration Project

5 min read  
最新 January 2025

FDA Issues Detailed Guidance for Biopharma Industry on What Information to Provide to FDA About Use of AI Models

A Seven-Step Process and Detailed Recommendations for Submissions
6 min read